Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30187
Title: Mas-related G protein-coupled receptor type D antagonism improves portal hypertension in cirrhotic rats.
Austin Authors: Gunarathne, Lakmie S;Rajapaksha, Indu G;Casey, Stephen ;Qaradakhi, Tawar;Zulli, Anthony;Rajapaksha, Harinda;Trebicka, Jonel;Angus, Peter W ;Herath, Chandana B
Affiliation: Gastroenterology and Hepatology
Medicine (University of Melbourne)
Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia
College of Health and Biomedicine, Victoria University, Werribee, Victoria, Australia
South Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Victoria, Australia
Oracle Australia, Melbourne, Victoria, Australia
Department of Internal Medicine, University Clinic Frankfurt, Frankfurt, Germany
Issue Date: 20-May-2022
Date: 2022
Publication information: Hepatology Communications 2022; 6(9): 2523-2537
Abstract: Splanchnic vasodilatation contributes to the development and aggravation of portal hypertension (PHT). We previously demonstrated that in cirrhosis, angiotensin- mediates splanchnic vasodilatation through the Mas receptor (MasR). In this study, we investigated whether the recently characterized second receptor for angiotensin-(1-7), Mas-related G protein-coupled receptor type D (MrgD), contributes to splanchnic vasodilatation in cirrhotic and noncirrhotic PHT. Splanchnic vascular hemodynamic and portal pressure were determined in two rat models of cirrhotic PHT and a rat model with noncirrhotic PHT, treated with either MrgD blocker D-Pro7 -Ang-(1-7) (D-Pro) or MasR blocker A779. Gene and protein expression of MrgD and MasR were measured in splanchnic vessels and livers of cirrhotic and healthy rats and in patients with cirrhosis and healthy subjects. Mesenteric resistance vessels isolated from cirrhotic rats were used in myographs to study their vasodilatory properties. MrgD was up-regulated in cirrhotic splanchnic vessels but not in the liver. In cirrhotic rats, treatment with D-Pro but not A779 completely restored splanchnic vascular resistance to a healthy level, resulting in a 33% reduction in portal pressure. Mesenteric vessels pretreated with D-Pro but not with A779 failed to relax in response to acetylcholine. There was no splanchnic vascular MrgD or MasR up-regulation in noncirrhotic PHT; thus, receptor blockers had no effect on splanchnic hemodynamics. Conclusion: MrgD plays a major role in the development of cirrhotic PHT and is a promising target for the development of novel therapies to treat PHT in cirrhosis. Moreover, neither MrgD nor MasR contributes to noncirrhotic PHT.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30187
DOI: 10.1002/hep4.1987
ORCID: 0000-0001-5841-057X
0000-0002-3326-3654
0000-0001-8505-2317
0000-0002-4403-7177
Journal: Hepatology Communications
PubMed URL: 35593203
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35593203/
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

28
checked on Apr 17, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.